

## Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the May 1, 2017 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at <https://www.ab.bluecross.ca/dbl/publications.html>

Please refer to the May 1, 2017 Updates for complete listings of products available by special authorization, step therapy/special authorization, products with changes to criteria for coverage, optional special authorization, added products, new established interchangeable groupings, least cost alternative (LCA) price changes, products with a price change and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at [https://www.ab.bluecross.ca/dbl/idbl\\_main1.html](https://www.ab.bluecross.ca/dbl/idbl_main1.html) is a near real-time application, and as such, contains the most up-to-date information.

### Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage for Ondansetron 4 mg/5 ml Oral Solution (DIN 02291967) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 19, 2017**.

#### ONDANSETRON HCL DIHYDRATE

##### 0.8 MG / ML ORAL SOLUTION

00002291967	ONDANSETRON	AAP	\$ 1.6028
00002229639	ZOFRAN	NOV	\$ 2.1258

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Doxepin 10 mg Capsule (DIN 02049996) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **May 22, 2017**.

#### DOXEPIN HCL

##### 10 MG CAPSULE

00002049996	APO-DOXEPIN	APX	\$ 0.2397
00000024325	SINEQUAN	APR	\$ 0.2677

... continued from previous page

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Apo-Indapamide 1.25 mg Tablet (DIN 02245246) manufactured by Apotex Inc., Jamp-Indapamide 1.25 mg Tablet (DIN 02373904), manufactured by Jamp Pharma Corporation, and Mylan-Indapamide 1.25 mg Tablet (DIN 02240067), manufactured by Mylan Pharmaceuticals ULC, Lozide 1.25 mg Tablet (DIN 02179709) manufactured by Servier Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. and Mylan Pharmaceuticals ULC have advised Alberta Blue Cross that the shortages of Apo-Indapamide 1.25 mg Tablet (DIN 02245246) and Mylan-Indapamide 1.25 mg Tablet (DIN 02240067) have been resolved.

As a result, Lozide 1.25 mg Tablet (DIN 02179709) will no longer be considered a temporary benefit for the *ADBL* after **May 24, 2017**.

---

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.686 2017/04

